

pCODR Clinician Conflict of Interest Declarations

Please Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	Mary Lynn Savoie		
Name of drug and indication under review:	blinatumomab (Blincyto) resubmission for the treatment of all adult patients with Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL), including those who have had one prior line of therapy (i.e., adult patients who are refractory or patients who are in first or later relapse).		
· · · · · · · · · · · · · · · · · · ·	• • • •		

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Se	ction A:	Payment Received				
1.	Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?					
		Yes No				
	If no,	please go to Section B				
2.	. What form of payment did you receive? (Check all that apply.)					
		Advisory role (e.g., advisory boards, HTA submission advice)		Program or Operating Funding (e.g., website)		
		Conference attendance		Research/educational grants		
		Royalties		Travel grants		
		Gifts		Sponsorship of Events		
		Honoraria		Other, please specify:	Sponsorship of the Canadian Society Hematology of which I am the current president	

	Please provide the names of companies and organizations and the amounts of the payments in the box below.
	Amgen - \$ total for 2 ad boards \$ honorarium for a post conference round table CHS received a total of \$ in 2016
Sect	ion B: Holdings or Other Interests
Have mutu	you received or is it in possession of stocks or options of more than \$10,000 (excluding lal funds) for organizations that may have a direct or indirect interest in the drug under law? If yes, please list in the table below.
No	
Sect	ion C: Affiliations, personal or commercial relationships
manu assoc	bu have personal or commercial relationships either with a drug or health technology ufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and ciated corporations) or other interest groups? If yes, please provide the names of the panies and organizations and outline the nature of these relationships in the table below.
No	
<u> </u>	
	eby certify that I have disclosed all relevant information with respect to any matter involving ty that may place me in a real, potential or perceived conflict of interest situation.
Dat	e: 2017/03/06 Name: Mary Lynn Savoie Signature:
	Morris